Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice

  title={Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice},
  author={Fei Yang and Shan Dang and Hong-jun Lv and Bingyin Shi},
  journal={Journal of International Medical Research},
  • Fei Yang, Shan Dang, B. Shi
  • Published 1 January 2021
  • Medicine, Biology
  • Journal of International Medical Research
Objectives Dipeptidyl peptidase-4 inhibition and gastric inhibitory polypeptide (GIP) receptor antagonism have therapeutic effects in type 2 diabetes mellitus. We assessed the effects of sitagliptin and Pro 3 (GIP) in a mouse model of diabetes. Methods Diabetes was induced in C57BL/6J mice by a high-fat diet and intraperitoneal injection of streptozocin. Blood glucose was assessed weekly. Six weeks later, serum triglycerides, total cholesterol and glucose tolerance were assessed and pancreatic… 
2 Citations

Figures and Tables from this paper

Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis
Sitagliptin alone or in combination with other antidiabetic agents significantly reduces serum TC and LDL-C in patients with type 2 diabetes mellitus, while no significant difference was observed in serum triglycerides or HDL-C.


GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
Data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.
Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
  • J. Kim
  • Medicine
    Diabetes & metabolism journal
  • 2015
Recently, the use of dipeptidyl peptidase-4 (DPP4) inhibitors in the management of type 2 diabetes mellitus (T2DM) has been widespread and sitagliptin may be one of appropriate treatment for T2DM in Asian patients.
Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
  • A. DobrianQ. Ma J. Nadler
  • Biology, Medicine
    American journal of physiology. Endocrinology and metabolism
  • 2011
Results indicate that sitagliptin has anti-inflammatory effects in adipose tissue and in pancreatic islets that accompany the insulinotropic effect.
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Overall, DPP-4 inhibitors appear to be a safe option for patients with type 2 diabetes, however, close pharmacovigilance is necessary to address the uncertainty regarding pancreas-related adverse events, while their potential impact on cardiovascular outcomes will be further elucidated after completion of more long-term studies.
Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats
Investigation of the effect of different antidiabetic drugs on serum levels of certain adipocytokines and nonesterified fatty acids in high-fat diet (HFD)/streptozotocin- (STZ-) induced diabetic rats found that metformin and sitagliptin increased serum adiponectin level, whereas they decreased serum leptin level.
Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum.
It is concluded that GIP, but not GLP-1, directly activates PepT1 activity by a cAMP-dependent signaling pathway in jejunum.
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Adding sitagliptin to BOT in Japanese T2DM patients appears to improve glycemic control without increasing endogenous insulin secretion and to reduce fasting and 2-hour postprandial PI/C-peptide ratios.
Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
It is indicated that DPP-4 inhibition has extrapancreatic protective effects against diet-induced adipose tissue inflammation and hepatic steatosis.
Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin
Observations indicate that in type 2 diabetes, the capacity of endogenous GIP to lower blood glucose is impaired; the effect of DPP-4 inhibition on glycemia is likely to depend on adequate endogenous GLP-1 release, requiring gastric emptying >2 kcal/min; and the action of metformin to lowerBlood glucose is not predominantly by way of the incretin axis.